VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | The benefit of double autologous transplantation in multiple myeloma patient subgroups

Pieter Sonneveld, MD, PhD, Erasmus University, Rotterdam, The Netherlands, discusses which patients with multiple myeloma may benefit from a second autologous stem cell transplant, explaining that multiple studies have suggested double transplantation may benefit those patients in terms of overall survival (OS) and progression-free survival (PFS). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Research funding from Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda; Advisory Board: Amgen, BMS, Celgene, Janssen, Karyopharm, Takeda.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter